Details of the Drug

General Information of Drug (ID: DMPR8E9)

Drug Name
Lonapegsomatropin
Synonyms ACP-001; TransCon-PEG Growth Hormone; TransCon-PEG-hGH; Growth hormone (TransCon, subcutaneous sustained-release), Ascendis Pharma
Indication
Disease Entry ICD 11 Status REF
Growth failure LD2F.1Y Approved [1]
Growth hormone deficiency 5A61.3 Phase 2 [2]
Affected Organisms
Humans
ATC Code
H01AC09: Lonapegsomatropin
H01AC: Somatropin and somatropin agonists
H01A: ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES
H01: PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H: SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
Cross-matching ID
UNII
OP35X9610Y
DrugBank ID
DB16220
TTD ID
D07GAA
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Somatotropin (GH1) TTT3YKH SOMA_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761177.
2 ClinicalTrials.gov (NCT01947907) Safety, PK/PD and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD). U.S. National Institutes of Health.